Articles tagged with Antivirals
A new study published in Microorganisms highlights the importance of small molecule drugs that target the unchanging parts of the SARS-CoV-2 virus. The research suggests that these stable targets could provide a consistent and reliable treatment option for COVID-19, even as vaccines are updated to address changing viral strains.
A global therapeutics development coalition is proposed to invigorate the pipeline and drive advocacy for increased investment. The coalition aims to develop two Phase-2 ready therapeutics for virus families of pandemic potential, with a focus on equitable access.
A recent study suggests that starting antiviral treatment as late as 14 days after COVID-19 infection can still provide benefits for immunocompromised patients. The research found that drugs like paxlovid and molnupiravir can inhibit virus replication, even if initiated up to 14 days after infection.
Researchers characterized bemnifosbuvir's activation cascade at atomic resolution, paving the way for the design of new broad-spectrum antiviral drugs. The study provides insights into the mechanism of action of this antiviral compound, which could lead to more effective treatments against various viral infections.
Researchers at the University of Virginia School of Engineering and Applied Science have designed a drug-carrying molecule that can slip past the lung's natural defenses. The nanocarrier, called PEG-BB, is shaped like a bottlebrush and mimics the properties of mucus, allowing it to move quickly through the airway.
Research from the University of Virginia School of Medicine reveals that nearly a quarter of children with recurrent wheezing have undetected lung infections that do not respond to commonly prescribed steroids. The study suggests that antiviral medications such as azithromycin may be a more effective treatment for these cases.
A new drug has shown promise in clearing HIV from the brain by targeting infected cells and reducing viral load. The treatment, BLZ945, successfully cleared the virus from brain tissue, providing a potential new avenue for HIV treatment.
Researchers at George Mason University's Center for Infectious Disease Research have made a breakthrough in finding a functional cure for HIV. Using an HIV-like virus particle called HIV Rev-dependent lentiviral vector, the team was able to reduce viral reservoirs and boost the immune system to produce antiviral neutralizing antibodies.
A 15-day course of nirmatrelvir-ritonavir did not demonstrate a significant improvement in select postacute sequelae of SARS-CoV-2 infection symptoms in vaccinated adults with prolonged symptom duration. Further studies are needed to determine the role of antivirals in PASC treatment.
Researchers at the University of North Carolina's Gillings School of Global Public Health have developed a new oral antiviral drug, obeldesivir (GS-5245), which has shown efficacy in treating COVID-19 in mice. The study suggests that obeldesivir could be a promising tool in future pandemic preparedness.
The study investigates the anticancer potential of CLK kinase inhibitors 1C8 and GPS167, which inhibit CLOCK kinases and affect cancer cell proliferation. The compounds also alter the expression and alternative splicing of transcripts involved in EMT and antiviral immune response.
A new Cochrane review suggests that taking zinc may reduce the duration of common cold symptoms by around two days, but the evidence is not conclusive. Common side-effects include bowel problems, nausea, and unpleasant taste.
Researchers from Osaka University found that influenza-associated brain disorders may be caused by the virus entering the brain and producing proteins. Antivirals blocking protein production are unlikely to be effective, but those targeting transcription and translation may offer hope for treatment.
A multicenter retrospective cohort study found that combining entecavir with Fuzheng Huayu reduced the cumulative incidence of hepatocellular carcinoma in patients with compensated chronic hepatitis B cirrhosis. The antifibrotic property of FZHY may be attributed to its beneficial effects on this population.
A new study published in eLife recommends taking Paxlovid three to five days after COVID-19 symptoms start to reduce viral loads and transmission. This optimal timing can help curb the spread of SARS-CoV-2 without population-wide restrictions.
Researchers deciphered the molecular structure of bulevirtide in complex with HBV/HDV receptor NTCP, revealing a unique 'plug' that inhibits virus entry. The study also sheds light on evolutionary adaptation of HBVs to host species and provides insights for developing smaller, more effective active agents.
A recent study published in Lancet Infectious Diseases found that vaccinated individuals had a lower risk of severe COVID-19 outcomes compared to unvaccinated individuals. The study also showed significant reductions in hospitalization and death rates from COVID-19, particularly among older individuals and those with compromised immune...
Researchers at the University of Alberta have discovered a new class of antiviral drugs that stimulate interferon production to reverse the effect of SARS-CoV-2 on cells. The study shows that these drugs can significantly reduce the amount of virus found in the lungs and prevent severe symptoms.
Researchers have identified macrophages, immune cells that gobble up foreign substances, in the pleural cavity around the lungs. These cells play a crucial role in reducing inflammation and disease during flu infections.
A new antiviral drug candidate has been found to improve flu vaccine efficacy and show promise against resistant virus variants. The study, published in PLoS Pathogens, tested the potential of 4'-fluorouridine as an influenza drug and found that resistant variants were severely weakened in mice and impaired in ferrets.
Researchers from UC San Francisco have found that Paxlovid treatment does not reduce the risk of developing long COVID. They also discovered a higher proportion of individuals with acute symptoms rebounding after treatment, and those who took Paxlovid were just as likely to develop severe Long COVID symptoms as those who did not.
Researchers have discovered that a nanoemulsion made from copaiba oil has antiviral effects against zika virus, showing 80% viral RNA inhibition. The study's results pave the way for developing medications or specific vaccines against zika.
A new study reports that antiviral medications are largely underused in young children diagnosed with influenza, highlighting opportunities for improvement in prevention and treatment. The study found low rates of antiviral use across all age groups, including a significant disparity in geographic regions.
Scientists have discovered that willow bark extract has a broad-spectrum antiviral effect against both enveloped and non-enveloped viruses, including coronaviruses and enteroviruses. The extract works by attacking the surface of the virus, preventing it from entering cells and reproducing.
Researchers at Hokkaido University identified 2-thiouridine as a broad-spectrum antiviral drug candidate targeting ssRNA+ viruses. It inhibits viral replication and increases survival rates in mice models for dengue and COVID-19.
Researchers have developed a lab-grown human skin model that effectively replicates mpox virus infections, providing insights into the virus's mechanisms of attack on skin cells. The study reveals how the virus causes disease and identifies potential therapeutic targets, including an antiviral drug called tecovirimat.
An observational study of nearly 70,000 COVID-19 patients found that Paxlovid lowered risk of death by 84% and Legevrio by 77%, reducing combined risk of hospitalization and death by over 40%. The treatments were effective across all patient subgroups and against newer Omicron subvariants.
Researchers have found a link between the antiviral drug molnupiravir and a pattern of mutations in the SARS-CoV-2 virus. The study used global sequencing databases to map mutations over time, identifying a mutational signature associated with individuals who took molnupiravir.
Researchers identified a new approach to treat poxviruses by targeting a cellular protein, making the virus more susceptible to natural defences. Existing immunosuppressive drugs can restrict replication and spread of poxviruses.
Researchers found that molnupiravir efficiently blocked SARS-CoV-2 transmission when administered at a human effect size-equivalent dose, but paxlovid did not. The study used ferret animal models and found that molnupiravir completely suppressed transmission at all tested doses.
Researchers developed a peptoid-based therapy that effectively inactivates three enveloped viruses, including Zika, Rift Valley fever and chikungunya virus, by disrupting their membranes. The approach targets specific lipids, allowing for preferential attack on the invader rather than the host.
Researchers have developed novel molecules that target the membrane of viruses, rather than their proteins, offering a promising new approach for treating infectious diseases. The molecules, inspired by natural peptides, disrupt the protective layers of enveloped viruses like Zika and chikungunya, while sparing human cells.
Researchers at the Indian Institute of Science have discovered picolinic acid's ability to disrupt viral entry into host cells, blocking enveloped viruses like SARS-CoV-2 and influenza A viruses. The compound targets a host-derived component of the virus, causing permanent damage while minimizing effects on the host cell.
New research reveals low use of monoclonal antibodies and oral antiviral drugs in US nursing homes, despite high risk of resident populations. The study analyzed data from the Center for Disease Control and Prevention National Healthcare Safety Network during the COVID-19 pandemic.
The Midwest AViDD Center has awarded $3 million in funding for six high-potential antiviral drug discovery projects targeting pandemic viruses such as SARS-CoV-2, Lassa and Ebola. These projects will expand the Center's expertise across disciplines to discover effective responses to pandemics and life-threatening infections.
Researchers at Max Delbrück Center developed a new model of the brain using human stem cells, which showed promise in treating HSV-1 induced encephalitis. By combining an anti-viral with an anti-inflammatory drug, they were able to prevent tissue damage and promote recovery.
Peruvoside has been discovered to prevent up to 12 medically important viruses, including SARS-CoV-2, Hand, Foot and Mouth Disease (HFMD), and Influenza. The compound acts on GBF1 protein, disabling its functionality and stopping virus production.
Researchers identified a single mutation in the hepatitis E virus polymerase that renders sofosbuvir therapy ineffective, resulting in a fivefold loss of efficacy. This discovery provides new insights into the development of future therapies against hepatitis E, which is responsible for 70,000 annual deaths globally.
Researchers used infected stem cells to study COVID-19's impact on organs, identifying effective anti-viral drugs for treatment. The study found distinct antiviral profiles in heart and lungs, paving the way for new therapeutic options.
A machine-learning study has found that individual characteristics, including age and weight, determine which drug combinations most effectively reduce COVID-19 recurrence rates. The study used real-world data from a hospital in China and identified unique treatment combinations for different demographic groups.
A team at Penn State has produced high-resolution images of SARS-CoV-2's protease protein and polyprotein complex. The research reveals a consistent order in which the proteins are cleaved, potentially supporting more efficient antiviral drugs.
Researchers at the University of Missouri identified occludin protein as a mediator for cell-to-cell transmission of coronavirus. The study found that damaged occludin protein enables virus replication and spread to neighboring cells, worsening symptoms.
Researchers deciphered the structure of the protein methyltransferase from the monkeypox virus, identifying a target for antiviral drugs. The findings may lead to the creation of new antivirals effective against not only monkeypox but also COVID-19.
Scientists have discovered potential broad-spectrum antivirals that target multiple families of RNA viruses, which pose a significant threat to future pandemics. The new agents showed promise in preventing and mitigating viral arthritis caused by Chikungunya virus and rescuing cells from harmful effects of other viruses.
A study found that adding rosmarinic acid to sunscreen increases sun protection factor by over 41% and reduces the need for synthetic chemicals. The natural antioxidant also provides anti-aging benefits, making it a potential multifunctional compound for improved skin health.
A study published in Journal of Hepatology found that some patients with chronic hepatitis B can achieve sustained immune control by discontinuing antiviral therapy after four years. This suggests a potential cure for the disease, which affects an estimated 350 million people worldwide.
Researchers found that after 96 weeks, some patients achieved loss of detectable HBsAg and reduced liver inflammation levels, indicating functional cure. The study suggests that discontinuing long-term antiviral therapy may be more effective than continuing it for certain patients.
A study published in Science Advances reveals that viral SARS-CoV-2 variants are developing resistance to protease inhibitors, including Paxlovid. Researchers warn that this could undermine the effectiveness of antiviral treatments and highlight the need for next-generation compounds with different resistance profiles.
A small molecule discovered by University of Houston researchers could potentially shorten the course of SARS-CoV-2 infection, offering a new alternative treatment option for COVID-19. The compound, CD04872SC, has shown promise in neutralizing the virus and its variants Delta and Omicron.
Three real-world studies published in the Journal of Hepatology and JHEP Reports demonstrate that bulevirtide is well-tolerated and safe for treating chronic hepatitis delta. Long-term suppressive therapy with BLV monotherapy has the potential to reduce viral replication and improve liver function in difficult-to-treat patients.
Researchers at the University of Bern have determined the structure of the canine distemper virus docking protein, enabling the development of tailor-made active substances to prevent virus entry into host cells. This breakthrough paves the way for novel therapies and antiviral drugs against this highly contagious viral disease.
UVA researchers discovered a metabolic pathway that can modulate COVID-19 inflammation, lung recovery, and host metabolic health. They suggest a potentially viable therapeutic agent that may be combined with existing anti-viral agents to treat severe COVID-19 in patients with underlying metabolic disease.
A Scripps Research and eMed study found that COVID-19 rebound cases are more common than previously reported, affecting up to 14.2% of Paxlovid-treated patients and 9.3% of untreated patients. Rebound is measured by positive test results or symptom recurrence after initial clearance.
Researchers from the University of Oxford-affiliated researchers found that high doses of ivermectin are ineffective in treating COVID-19. The study used the PLATCOV trial to compare the rates at which different drugs reduced the viral load of SARS-CoV-2, and the results suggest that ivermectin does not have measurable antiviral activity.
A new analysis of COVID-19 patient data reveals that remdesivir significantly lowers mortality in unvaccinated patients with conventional oxygen support. The study found no evidence of varying treatment effects based on age, comorbidities, or inflammation levels.
The US Preventive Services Task Force (USPSTF) recommends against routine serologic screening for genital herpes simplex virus infection, even in symptomatic individuals. The lifelong nature of HSV infection means there is no cure, but antiviral medications can provide clinical benefits to those experiencing symptoms.
A new class of SARS-CoV-2 antibodies has been shown to neutralise multiple variants of the virus, providing hope for a better antiviral medication. The antibodies work by attaching to a partially hidden part of the virus' spike protein that would be difficult for it to mutate.
A study by Pusan National University researchers investigates the effects of mild acid hydrolysis on sulfated fucans in sea cucumbers and sea urchins. The results show selective 2-desulfation, leading to an 8-sugar-long oligosaccharide production.
Researchers from the University of Colorado found that Paxlovid significantly reduced rates of hospitalization and death among non-hospitalized patients infected with recent Omicron subvariants. The study used real-world data from 28,000 patients and suggested a benefit for Paxlovid in preventing severe disease.
A large Dutch study found that the BCG vaccine does not protect elderly people with co-morbidities against COVID-19 symptoms. The study analyzed 6,112 participants and showed no difference in disease manifestations or hospitalizations between those who received the vaccine and those who received a placebo.